Incohercible hematuria in polycystic kidney disease: successful treatment using superselective arterial embolization

Leonardo Sivak Nefrología Swiss Medical Group, Buenos Aires
Guillermo Eisele Servicio de Hemodinamia y Radiología Intervencionista, Sanatorio de los Arcos, Buenos Aires
Oscar Vargas Servicio de Hemodinamia y Radiología Intervencionista, Sanatorio de los Arcos, Buenos Aires
Harvey Manosalva Servicio de Hemodinamia y Radiología Intervencionista, Sanatorio de los Arcos, Buenos Aires

Keywords: polycystic kidney disease, superselective artery embolization, hematuria, therapy

References

Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol. 2002;13(9):2384-98.

Reeders ST, Breuning MH, Davies KE, Nicholls RD, Jarman AP, Higgs DR, Pet al. A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16. Nature. 1985;317(6037):542-4.

Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418-28.

Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int. 2000;58(3):925-43.

Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int. 2005;67(4):1234-47.

Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999;353(9147):103-7.

Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol. 2009;20(8):1833-8.

Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens. 2009;18(2):99-106.

Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomal-dominant Polycystic Kidney disease. Kidney Int. 2001;60(1):37-45.

Wei W, Popov V, Walocha JA, Wen J, Bello-Reuss E. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int. 2006;70(7):1261-8.

Cornec-Le Gall E, Audrézet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016;27(3):942-51.

Peces Serrano R, Aguilar A, Vega C, Cuesta López E, Peces C, Selgas Gutiérrez R. Tratamiento con ácido tranexámico de la hematuria incoercible en la poliquistosis renal autosómica dominante. Nefrología (Madr). 2012;32(2):160-65.

Harley JD, Shen FH, Carter SJ. Transcatheter infarction of a polycystic kidney for control of recurrent hemorrhage. AJR Am J Roentgenol. 1980;134(4):818-20.

Grantham J, Winklhofer F. Cystic disease of the kidney. In: Brenner & Rector´s The Kidney. Philadelphia, PA: WB Saunders, 2003; pp 1743-1777.

Hoshino J, Suwabe T, Hayami N, Sumida K, Mise K, Kawada M, et al. Survival after arterial embolization therapy in patients with polycystic kidney and liver disease. J Nephrol. 2015;28(3):369-77.

Published

2014-09-01

How to Cite

Sivak L, Eisele G, Vargas O, Manosalva H. Incohercible hematuria in polycystic kidney disease: successful treatment using superselective arterial embolization. Rev Nefrol Dial Traspl. [Internet]. 2014Sep.1 [cited 2024Dec.27];34(3):155-8. Available from: http://revistarenal.org.ar/index.php/rndt/article/view/117